ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Effect of improved Yupingfeng powder prescription on interleukin-33/suppression of tumorigenicity 2 pathway in mice with ovalbumins-induced allergic rhinitis.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interleukin-Mediated Macrophage Polarization in Allergic Rhinitis Inflammation: A Systematic Review.Journal of inflammation research · 2026Review
- IL-Mediated Macrophage Polarization Axis: From Inflammatory Positive Feedback Loop to Precision Biomarkers and Therapeutic Targets for Allergic Rhinitis-A Narrative Review.Journal of asthma and allergy · 2026Review
- Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo identify the main active ingredients of Improved Yupingfeng Powder prescription (IYPFP, ) and investigate its anti-inflammatory effects and underlying mechanisms in ovalbumins (OVA)-induced allergic rhinitis (AR) in mice.
methodsBagg Albino/substrain mice were sensitized with OVA emulsified in aluminum hydroxide adjuvant, followed by intranasal challenge to establish AR models. Treatment groups received IYPFP (1.5 or 4.5 g/kg)
resultsEight chemical compounds of IYPFP were accurately identified, they are prim-O-glucosylcimifugin (peak 2), calycosin-7-O-β-D-glucoside (peak 4), cimifugin (peak 5), 5-O-methylvisammioside (peak 6), sec-O-glucosylhamaudol (peak 12), calycosin (peak 15), formononetin (peak 19), and magnolin (peak 21). Compared with the OVA model group, IYPFP alleviated the nasal symptoms, improved nasal mucosal injury and downregulated the levels of OVA-specific IgE, histamine and IL-33. Additionally, IYPFP reduced the levels of IL-5, IL-13, TNF-α, IL-33, and ST2 in the lungs, but upregulated IFN-γ. Molecular docking confirmed that eight representative compounds of IYPFP had good binding properties with IL-5, IL-13, IFN-γ, histamine, IL-33 and ST2, and were able to inhibit the activation of the IL33/ST2 inflammatory pathway.
conclusionThis study demonstrates that IYPFP ameliorates AR by modulating IL-33/ST2 pathway which provides a theoretical basis for the clinical treatment of patients with AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.